Adjuvant endocrine therapy for premenopausal women with early breast cancer

被引：11

作者：

Bao, Ting ^{[1
]}

Davidson, Nancy E. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA

来源：

BREAST CANCER RESEARCH | 2007年 / 9卷 / 06期

关键词：

D O I：

10.1186/bcr1830

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.

引用

页数：3

共 11 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

Beatson G.T., 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7

[3]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[4]

Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review [J].

Clarke, MJ .

BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7167) :1246-1248

[5]

Cuzick J, 2007, LANCET, V369, P1711

[6]

Adjuvant endocrine therapy for premenopausal women with early breast cancer [J].

Dellapasqua, S ;

Colleoni, M ;

Gelber, RD ;

Goldhirsch, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) :1736-1750

[7]

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes [J].

Goetz, MP ;

Rae, JM ;

Suman, VJ ;

Safgren, SL ;

Ames, MM ;

Visscher, DW ;

Reynolds, C ;

Couch, FJ ;

Lingle, WL ;

Flockhart, DA ;

Desta, Z ;

Perez, EA ;

Ingle, JN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9312-9318

[8]

Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 [J].

Goldhirsch, A. ;

Wood, W. C. ;

Gelber, R. D. ;

Coates, A. S. ;

Thuerlimann, B. ;

Senn, H.-J. ;

Members, Panel .

ANNALS OF ONCOLOGY, 2007, 18 (07) :1133-1144

[9]

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations [J].

Rebbeck, TR ;

Lynch, HT ;

Neuhausen, SL ;

Narod, SA ;

van't Veer, L ;

Garber, JE ;

Evans, G ;

Isaacs, C ;

Daly, MB ;

Matloff, E ;

Olopade, OI ;

Weber, BL .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) :1616-1622

[10]

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women [J].

Robertson, JFR ;

Blamey, RW .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (07) :861-869

← 1 2 →